Helix BioPharma's total assets for Q3 2025 were C$1.01M, a decrease of -55.00% from the previous quarter. TSE:HBP total liabilities were C$2.40M for the fiscal quarter, a 6.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.